New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 3 of 8
The Cultural Formulation Interview-Engagement Aid
NCT03044145
Pharmacogenetics of Naltrexone for Stimulant Abuse
NCT03226223
Cannabinoid Medication for Adults With OCD
NCT02911324
A Study of L-DOPA for Depression and Slowing in Older Adults
NCT02744391
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
NCT02803229
Remediation of Auditory Recognition in Schizophrenia With tDCS
NCT02869334
Brief Intervention to Reduce Fear of Public Speaking
NCT02790736
Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)
NCT02645929
Neural Mechanisms of Disulfiram Effects
NCT02735577
Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome
NCT02687165
Dietary Flavanols and Dentate Gyrus Function
NCT02312310
Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults
NCT02530645
Nabilone in Cannabis Users With PTSD
NCT03251326
Medication-Assisted Treatment for Youth With Substance Use Disorders
NCT02593474
Changing Habits in Anorexia Nervosa: Novel Treatment Development
NCT02382055
Gabapentin in Patients at Clinical Risk for Psychosis
NCT02557945
Glutamatergic Modulation of Disordered Alcohol Use
NCT02539511
Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.
NCT02255357
Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
NCT02422290
Personalized Computerized Inhibitory Control Training for OCD
NCT02378896
The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances
NCT02429674
Biosignatures of Latuda for Bipolar Depression
NCT02239094
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
NCT02473250
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
NCT02437344
The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving
NCT02316574
Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
NCT02373124
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
NCT02267629
Overlapping Neural Circuits in Pediatric OCD
NCT02421315
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
NCT02088177
Control and Reward Circuits in Obsessive Compulsive Disorder
NCT02221518
Treatment Outcome in CBT for Cocaine Use
NCT03538548
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
NCT02294253
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
NCT02259517
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
NCT02206776
Risks and Benefits of Naloxone Prescribing
NCT02535494
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence
NCT01468012
Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep
NCT02189213
Treatment of Psychosis and Agitation in Alzheimer's Disease
NCT02129348
Biomarker Assessment of Glutamatergic Target Engagement
NCT02134951
Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS
NCT02140775
Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression
NCT02750631
Social Circumstances, Parenting Techniques, and Infant Development
NCT02121496
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
NCT01973283
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
NCT02034474
Imaging Dopamine Release in Depression
NCT02033369
A Sequenced Behavioral and Medication Intervention for Cocaine Dependence
NCT01986075
Vilazodone for Separation Anxiety Disorder
NCT01999920
Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
NCT02062658
Dyadic Therapy for Mothers and Children
NCT02123160
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.